Sex and age distribution of global disease burden of calcific aortic valve disease.
10.3724/zdxbyxb-2024-0610
- Author:
Xiangning DENG
1
,
2
;
Xinyu SUI
3
;
Nan LI
4
;
Jieli FENG
3
;
Shaomin CHEN
3
;
Xinye XU
3
;
Yida TANG
3
;
Yupeng WANG
2
,
5
Author Information
1. Department of Cardiology, Peking University Third Hospital, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China. sangengsai@
2. com.
3. Department of Cardiology, Peking University Third Hospital, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China.
4. Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China.
5. Department of Cardiology, Peking University Third Hospital, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing 100191, China. wangyp007@
- Publication Type:Journal Article
- Keywords:
Age-specific differences;
Calcific aortic valve disease;
Gender differences;
Global burden of disease
- MeSH:
Humans;
Male;
Female;
Aged;
Calcinosis/mortality*;
Prevalence;
Global Burden of Disease;
Aged, 80 and over;
Middle Aged;
Aortic Valve/pathology*;
Aortic Valve Stenosis/epidemiology*;
Age Distribution;
Adult;
Disability-Adjusted Life Years;
Sex Distribution;
Global Health;
Aortic Valve Disease/epidemiology*;
Sex Factors
- From:
Journal of Zhejiang University. Medical sciences
2025;54(1):21-27
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To analyze sex and age distribution of global disease burden of calcific aortic valve disease (CAVD) from 1990 to 2021.
METHODS:CAVD data during 1990-2021 were obtained from the IHME website for Global Burden of Disease (GBD). The prevalence, mortality, years lived with disability (YLDs), and disability-adjusted life years (DALYs) were analyzed by gender and age groups. Joinpoint regression was used to calculate annual percentage change (APC) and average annual percentage change (AAPC).
RESULTS:In 2021, there were 13.32 million CAVD patients and 142 000 deaths caused by CAVD globally. Age-standardized prevalence was higher in males (193.2/105) than that in females (128.9/105). Patients in 65-<85 age group accounted for 64.0% of total cases, while those ≥85 years old accounted for 16.1%. From 1990 to 2021, prevalence increased in both sexes with an AAPC of 0.72% for males and 0.57% for females, respectively. Prevalence grew fastest from 2000 to 2010, slowed thereafter, and declined from 2015 to 2021. In <65 years old, the mortality of males was 2.4 times higher than that of females, while in ≥85 years old, mortality of females (117.3/105) exceeded that of males (99.1/105). YLD rates increased with age, and were higher in males for all age groups. DALY rates decreased overall but increased in ≥85 years old, with a greater increase in females.
CONCLUSIONS:There are significant gender and age disparities in global disease burden of CAVD, with the elderly, especially super-elderly females deserving particular attention. It is recommended to develop personalized intervention strategies for these populations.
